Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2013
03/21/2013CA2848017A1 Use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro- 2h-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases
03/21/2013CA2847915A1 Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
03/21/2013CA2847892A1 Compounds and pharmaceutical compositions for the treatment of viral infections
03/21/2013CA2847842A1 Pharmaceutical compositions
03/21/2013CA2847698A1 Nanoconjugates able to cross the blood-brain barrier
03/21/2013CA2847613A1 Tamper resistant immediate release formulations
03/21/2013CA2847611A1 Tamper resistant pharmaceutical formulations
03/21/2013CA2847355A1 Methods for treating hcv
03/21/2013CA2847293A1 Solid forms of a transthyretin dissociation inhibitor
03/21/2013CA2847266A1 New enzyme inhibitor compounds
03/21/2013CA2847193A1 New enzyme inhibitor compounds
03/21/2013CA2847091A1 Compositions and methods for treating cancer using pi3k.beta. inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
03/21/2013CA2846824A1 Pharmaceutical composition for inhalation
03/21/2013CA2846785A1 New dihydroquinoline-2-one derivatives
03/21/2013CA2846768A1 Combinations comprising a s1p receptor modulator
03/21/2013CA2846686A1 Sorbent comprising on its surface an aliphatic unit having an anionic or deprotonizable group for the purification of organic molecules
03/21/2013CA2846366A1 Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
03/21/2013CA2846347A1 Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
03/21/2013CA2846107A1 Nitrogen containing compounds and their use
03/21/2013CA2845868A1 Use of omega fatty acids for treating disease
03/21/2013CA2845806A1 Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
03/21/2013CA2845673A1 Pharmaceutical nanoparticle compositions
03/21/2013CA2845473A1 Indanyl-substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
03/21/2013CA2845007A1 Noribogaine salt ansolvates
03/21/2013CA2844923A1 Aqueous compositions comprising arbekacin
03/21/2013CA2844865A1 3-pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents
03/21/2013CA2844835A1 N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides
03/21/2013CA2844834A1 5-cycloalkyl- or 5-heterocyclyl-nicotinamides
03/21/2013CA2844830A1 Novel imidazole amines as modulators of kinase activity
03/21/2013CA2844704A1 Aminopyrimidine derivatives for use as modulators of kinase activity
03/21/2013CA2844617A1 Pyrrolidine-3-ylacetic acid derivative
03/21/2013CA2844577A1 Microrna inhibitors
03/21/2013CA2844142A1 Method for enhancing the growth and fullness of hair
03/21/2013CA2840242A1 Methods for treating hcv
03/20/2013EP2570441A2 Bioabsorbable surgical composition
03/20/2013EP2570418A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound
03/20/2013EP2570417A1 Thienopyridine ester derivative containing nitrile, preparation method, use and composition thereof
03/20/2013EP2570415A1 N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals
03/20/2013EP2570414A1 Heterocyclic aromatic compounds useful as growth hormone secretagogues
03/20/2013EP2570413A1 Benzothiazinone derivatives as anti-tuberculosis agents
03/20/2013EP2570411A1 Nitrogen-containing heterocyclic compound having kynurenine production inhibitory activity
03/20/2013EP2570410A1 1-[(4-hydroxypridin-4-yl) methyl]pyridine-2(1h)-one derivatives, preparation methods and uses thereof
03/20/2013EP2570409A1 Aralkyl diamine derivatives and uses thereof as antidepressant
03/20/2013EP2570408A1 Hexaketide compound and medicinal use thereof
03/20/2013EP2570407A1 Tetrazole-substituted arylamide derivatives and their use as P2x3 and/or P2x2/3 purinergic receptor antagonists
03/20/2013EP2570405A1 Synthesis of Triazolopyrimidine Compounds
03/20/2013EP2570403A1 Urea compounds and use thereof for inhibiting apoptosis
03/20/2013EP2570402A1 Bi-aryl derivatives, their preparation and their therapeutic application
03/20/2013EP2570181A1 Sorbent comprising its surface an aliphatic unit having an anionic or deprotonizable group for the purfication of organic molecules
03/20/2013EP2570155A2 Treatment of depressive disorders
03/20/2013EP2570132A2 Method for preparing novel processed ginseng or an extract thereof, the usually minute ginsenoside content of which is increased
03/20/2013EP2570130A1 Therapeutic agents containing bacteriophages against P. aeruginosa
03/20/2013EP2570128A1 Muscarinic acetylcholine receptor antagonists
03/20/2013EP2570127A1 Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
03/20/2013EP2570126A1 Use of melatonine for treating acute alcohol intoxication
03/20/2013EP2570125A1 Ep1 receptor ligands
03/20/2013EP2570124A1 Oleuropein compositions for healing wounds and ulcers in elderly people and/or diabetics
03/20/2013EP2570123A1 Use of 2,4-dichlorobenzyl alcohol having an anaesthetic effect
03/20/2013EP2570121A1 Slow release tablet of elemene anti-tumor plant medicine
03/20/2013EP2570120A1 Coated particle and method for producing coated particle
03/20/2013EP2570118A1 Combinations of hyaluronic acid and a vitamin for inhibiting inflammation
03/20/2013EP2570117A1 Pharmaceutical topical compositions
03/20/2013EP2569450A1 Compositions and methods for targeting a3g:rna complexes
03/20/2013EP2569434A2 Compositions and methods for treating leukemia
03/20/2013EP2569432A2 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
03/20/2013EP2569431A1 Antisense modulation of interleukins 17 and 23 signaling
03/20/2013EP2569429A1 Compositions and methods for modulating metabolism
03/20/2013EP2569325A1 Method of reducing intraocular pressure in humans using n6 - cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
03/20/2013EP2569324A1 Aminoglycoside derivatives
03/20/2013EP2569322A1 Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity
03/20/2013EP2569320A2 (+)-3-hydroxymorphinan-based polycycle derivatives as neuroprotectants
03/20/2013EP2569319A1 Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
03/20/2013EP2569318A1 Novel compounds
03/20/2013EP2569317A1 Spirocyclic derivatives with affinity for calcium channels
03/20/2013EP2569316A1 Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
03/20/2013EP2569315A1 Fused bicyclic kinase inhibitors
03/20/2013EP2569314A1 Fused bicyclic kinase inhibitors
03/20/2013EP2569313A1 Compounds useful as inhibitors of atr kinase
03/20/2013EP2569312A1 Substituted heterocyclyl benzyl pyrazoles, and use thereof
03/20/2013EP2569310A1 Morpholine compounds as mineralocorticoid receptor antagonists
03/20/2013EP2569309A1 Hydroxyalkyl benzyl pyrazoles, and use thereof for the treatment of hyperproliferative and angiogenic diseases
03/20/2013EP2569308A1 New cyclohexylamine derivatives having 2 adrenergic agonist and m3 muscarinic antagonist activities
03/20/2013EP2569307A2 Lipoic acid and nitroxide derivatives and uses thereof
03/20/2013EP2569306A1 Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
03/20/2013EP2569305A1 Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
03/20/2013EP2569304A1 Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
03/20/2013EP2569303A1 Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
03/20/2013EP2569302A1 Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
03/20/2013EP2569301A1 Indazole inhibitors of kinase
03/20/2013EP2569300A1 Nitrogen heterocyclic compounds useful as pde10 inhibitors
03/20/2013EP2569299A1 Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
03/20/2013EP2569298A1 Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
03/20/2013EP2569297A1 Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
03/20/2013EP2569296A1 Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
03/20/2013EP2569294A1 Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
03/20/2013EP2569293A1 Pyrazolopyridines as inhibitors of the kinase lrrk2
03/20/2013EP2569292A1 Polysubstituted benzofurans and medicinal applications thereof
03/20/2013EP2569291A1 Selective glycosidase inhibitors and uses thereof
03/20/2013EP2569290A2 Pharmaceutical compounds
03/20/2013EP2569285A1 Bifunctional quinoline derivatives
1 ... 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 ... 7860